Stock Markets March 25, 2026

J.P. Morgan Initiates Overweight on Talanx, Targets €125 as Reserve Build Approaches Release Point

Broker cites valuation gap between primary insurance and Hannover Re stake, anticipates easing reserve headwind to lift earnings

By Sofia Navarro
J.P. Morgan Initiates Overweight on Talanx, Targets €125 as Reserve Build Approaches Release Point

J.P. Morgan began coverage of Talanx AG with an overweight rating and set a €125 price target for December 2027, implying roughly 21% upside from the recent close of €103. The bank argues the market undervalues Talanx's primary insurance operations relative to its 50.2% stake in Hannover Re, and sees reserve buffer accumulation nearing a level that should reduce its drag on reported results.

Key Points

  • J.P. Morgan initiated coverage of Talanx AG with an overweight rating and a €125 price target for December 2027, implying roughly 21% upside from a €103 close.
  • The broker values the standalone primary insurance business at about 7.8x 2027 estimated earnings after excluding Talanx's 50.2% stake in Hannover Re, versus a group multiple of 9.3x.
  • Reserve accumulation - with group buffers reported significantly above €5 billion and a primary insurance buffer estimated above €2.3 billion - is central to the thesis, as management signals the buffer is near the top of its target range and related earnings drag should lessen.

Overview

J.P. Morgan has opened coverage on German insurer Talanx AG with an "overweight" recommendation and a December 2027 price objective of €125. That target sits approximately 21% above the company's closing share price of €103 on Tuesday, per the bank's note.

Valuation split and the Hannover Re holding

Stripping out Talanx's 50.2% ownership of listed reinsurer Hannover Re, J.P. Morgan calculates the market is effectively valuing the standalone primary insurance business at about 7.8 times estimated 2027 earnings. By contrast, the brokerage cites a group-level multiple of 9.3 times. The bank's sum-of-the-parts valuation applies a 10x multiple to 2028 earnings for the primary businesses and incorporates J.P. Morgan's own €290 price target for the Hannover Re stake to arrive at the €125 target.

Track record and the reserve thesis

Analysts at J.P. Morgan note Talanx's performance since 2021 has not only met expectations but has materially outperformed company guidance, arguing the valuation gap between the group's primary activities and its reinsurance holding is unjustified on that basis. Central to the bank's investment thesis is the insurer's recent reserve behaviour.

At Talanx's full-year 2025 earnings call on March 18, management indicated total group reserve buffers were "significantly" above €5 billion. J.P. Morgan estimates that the primary insurance segment alone now holds a buffer in excess of €2.3 billion - roughly double that segment's 2025 earnings. The bank also notes that active reserve-building over the prior three years likely added an estimated 1.5 to 2 percentage points annually to the primary insurance combined ratio, representing a drag on near-term reported results.

With management signalling the group buffer is near the top of its stated target range, J.P. Morgan expects this reserve-related drag to ease going forward, which should support improvements in reported earnings for the primary insurance operations.

Segment contribution and financial metrics

J.P. Morgan highlights that Talanx's primary insurance divisions - Corporate & Specialty, Retail International and Retail Germany - accounted for roughly 50% of group earnings in 2025. That is a marked increase from about 25% a decade earlier, with absolute earnings in the primary insurance businesses rising more than sixfold. The group's primary combined ratio was 91.1% in 2025 and the Solvency II ratio was reported at 240%.

Earnings, dividends and consensus positioning

J.P. Morgan models group net income of €2.81 billion for 2026, which is above Talanx's own guidance of approximately €2.7 billion. The bank forecasts earnings per share of €10.87 for 2026, increasing to €11.58 by 2028. Its net income estimates sit about 2% ahead of Bloomberg consensus for 2026-27 and about 6% ahead for 2028.

On shareholder returns, J.P. Morgan projects a dividend of €4.45 per share for 2026, higher than Talanx's guidance of more than €4. The bank's dividend estimates run ahead of consensus by roughly 10%, 8% and 4% through 2026-28, respectively.

Downside risks and sensitivities

J.P. Morgan identifies a set of downside risks to its thesis, including the potential for large catastrophe losses, a sharper-than-expected pricing deterioration in Corporate & Specialty and P&C Reinsurance, and adverse moves in financial markets. Among market risks, the brokerage highlights widening credit spreads as the most material sensitivity to its valuation and earnings assumptions.

Disclosure

The bank disclosed existing commercial relationships with Talanx and indicated it expects to seek investment banking compensation from the company within three months.


This article presents the broker view and the firm's estimates as reported by J.P. Morgan; it does not add or amend the figures provided by the bank.

Risks

  • Catastrophe losses that could materially affect underwriting results - this primarily impacts the property & casualty insurance and reinsurance sectors.
  • A sharper-than-expected pricing downturn in Corporate & Specialty and P&C Reinsurance, which would pressure combined ratios and profitability in those insurance segments.
  • Adverse financial market moves, with widening credit spreads identified as the most material sensitivity to valuation and earnings estimates, affecting the broader financial and insurance markets.

More from Stock Markets

Morgan Stanley Raises Prosus to Overweight, Cites Peak NAV Discount and 29% Upside Mar 25, 2026 Quartix Posts Double-Digit Top-Line Growth, Boosts Profitability in 2025 Mar 25, 2026 Franchise Brands posts modest system sales rise as earnings hold steady Mar 25, 2026 Pharos Energy posts lower 2025 revenue as oil prices weigh on sales Mar 25, 2026 Aptamer Group posts 27% H1 revenue rise as pharma contracts underpin growth Mar 25, 2026